Anticoagulation with Intravenous Direct Thrombin Inhibitors in Pediatric Extracorporeal Membrane Oxygenation: A Systematic Review of the Literature
The objective of this systematic review was to characterize DTI types, dosing, monitoring, and outcomes (bleeding and thromboembolic) in pediatric ECMO patients managed with IV DTIs. We conducted searches of MEDLINE (Ovid) and Embase (Elsevier) from inception through December 2022. Case reports, retrospective studies, and prospective studies providing per-patients or summary data for patient(s) <18 years of age receiving IV DTI for ECMO anticoagulation were included. Study selection and data extraction were conducted independently by two reviewers. A total of 28 studies: 14 case reports, 13 retrospective studies, and 1 ...
Source: Seminars in Thrombosis and Hemostasis - August 29, 2023 Category: Hematology Authors: Kiskaddon, Amy L. Do, Nhue L. Williams, Pamela Betensky, Marisol Goldenberg, Neil A. Tags: Review Article Source Type: research
Anticoagulation strategies in patients with extracorporeal membrane oxygenation: a network meta ‐analysis and systematic review
ConclusionsCompared with UFH and Arg, Biv reduces the risk of thrombosis and appears to be a better choice for patients requiring ECMO. NM was associated with a reduced risk of in-hospital mortality. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - August 4, 2023 Category: Drugs & Pharmacology Authors: Jiale Chen,
Guoquan Chen,
Wenyi Zhao,
Wenxing Peng Tags: REVIEW Source Type: research
Bivalirudin or heparin for systemic anticoagulation during pediatric extracorporeal membrane oxygenation: Multicenter retrospective study
The objective of this study is to evaluate the outcomes of unfractionated heparin (UFH) compared to bivalirudin anticoagulation in pediatric ExtraCorporeal Membrane Oxygenation (ECMO). (Source: Thrombosis Research)
Source: Thrombosis Research - July 24, 2023 Category: Hematology Authors: Mohammed Hamzah, Troy G. Seelhammer, Asaad G. Beshish, Jonathan Byrnes, Mouhammad Yabrodi, Adam Szadkowski, Riad Lutfi, Nicole Andrijasevic, Kristal Hock, Sarah Worley, Duncan J. Macrae Tags: Full Length Article Source Type: research
Use of ecarin chromogenic assay during bivalirudin anticoagulation in adult extracorporeal membrane oxygenation
Bivalirudin directly inhibits clot-bound and circulating thrombin without requiring cofactors, has a short half-life, and lacks immunogenicity, making it an attractive anticoagulant over heparin during extracorporeal membrane oxygenation (ECMO) [1]. Empirical evidence demonstrates a favorable safety and efficacy profile of bivalirudin, and that it may result in increased time in therapeutic range compared to heparin during ECMO [2]. However, an assay that reliably quantifies bivalirudin anticoagulant effect is critical in preventing thrombus deposition and minimizing bleeding complications during the high stakes' context o...
Source: Thrombosis Research - May 29, 2023 Category: Hematology Authors: Abby K. Krauter, Scott D. Nei, Troy G. Seelhammer, J. Kyle Bohman, Patrick M. Wieruszewski Tags: Letter to the Editors-in-Chief Source Type: research
Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study
CONCLUSIONS: The anticoagulation strategy of bivalirudin bridging fondaparinux seems to be superior to that of bivalirudin bridging enoxaparin in patients with AMI undergoing PPCI.PMID:36817677 | PMC:PMC9897106 | DOI:10.5114/aoms/157287 (Source: Archives of Medical Science)
Source: Archives of Medical Science - February 23, 2023 Category: Biomedical Science Authors: Yanqing Guo Jingping Wang Zhixin Wang Li Li Jian An Source Type: research
Use of Bivalirudin for Chronic Total Occlusion Percutaneous Intervention: Insights From the PROGRESS-CTO Registry
CONCLUSION: Bivalirudin is infrequently used during retrograde CTO-PCI. While the incidence of adverse events was similar with unfractionated heparin, larger studies are needed to assess the safety of bivalirudin.PMID:36821841 (Source: The Journal of Invasive Cardiology)
Source: The Journal of Invasive Cardiology - February 23, 2023 Category: Cardiology Authors: Louis Verreault-Julien Bahadir Simsek Spyridon Kostantinis Athanasios Rempakos Judit Karacsonyi Taral N Patel Brian K Jefferson Mitul Patel Paul B Poommipanit Barry F Uretsky Khaldoon Alaswad Sevket Gorgulu Omer Goktekin Jaikirshan Khatri Dmitrii Khelimsk Source Type: research
